Acetylcysteine - CAS 616-91-1
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acetylcysteine
Catalog Number:
616-91-1
Synonyms:
SME-3110, MK-264, DU-23000
CAS Number:
616-91-1
Description:
Acetylcysteine is used mainly as a mucolytic, protects against acetaminophen overdose-induced hepatotoxicity by maintaining or restoring hepatic concentrations of glutathione.
Molecular Weight:
163.19
Molecular Formula:
C5H9NO3S
COA:
Inquire
MSDS:
Inquire
Targets:
Others
Chemical Structure
CAS 616-91-1 Acetylcysteine

Related Products


CAS 61-78-9 4-Aminohippuric Acid

4-Aminohippuric Acid
(CAS: 61-78-9)

4-Aminohippuric acid is a typical substrate of organic anion transport systems.

NSC-601980 analog
(CAS: 91757-46-9)

NSC-601980 analog is the analog of the NSC601980, which shows antitumor activity in the yeast screening experiment.

CAS 93479-97-1 Glimepiride

Glimepiride
(CAS: 93479-97-1)

Glimepiride is a medium- to long-acting sulfonylurea antidiabetic drug.

Dirlotapide
(CAS: 481658-94-0)

Dirlotapide is a drug used to treat obesity in dogs works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor.

CAS 143558-00-3 Rocuronium

Rocuronium
(CAS: 143558-00-3)

Rocuronium is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia.

CAS 1084-65-7 Meticrane

Meticrane
(CAS: 1084-65-7)

Meticrane, a sulphonamide derivative, is an effective diuretic and also an inhibitor of peripheral-type benzodiazepine receptor. IC50: 1 μM.

CAS 136-40-3 Phenazopyridine Hydrochloride

Phenazopyridine Hydrochloride
(CAS: 136-40-3)

Phenazopyridine Hydrochloride is a local analgesic that has been used in urinary tract disorders.

Gemilukast disodium salt
(CAS: 1232861-64-1)

CAS 50-03-3 Hydrocortisone acetate

Hydrocortisone acetate
(CAS: 50-03-3)

Hydrocortisone acetate, a derivative of hydrocortisone, is a corticosteroid compound that has a broad range of anti-inflammatory and immunosuppressive effects a...

AZ7371
(CAS: 1494675-86-3)

AZ7371 is a a novel non-covalent DprE1 inhibitor. .

CAS 11088-09-8 Wilforine

Wilforine
(CAS: 11088-09-8)

Wilforine, a sesquiterpene pyridine alkaloid, is effective in treating idiopathic pulmonary fibrosis.

CAS 586357-02-0 O-Desmethyl Mebeverine Acid

O-Desmethyl Mebeverine Acid
(CAS: 586357-02-0)

O-Desmethyl Mebeverine Acid is a metabolite of Mebeverine, which is an antispasmodic.

CAS 188627-80-7 Eptifibatide

Eptifibatide
(CAS: 188627-80-7)

A Arginin-glycin-aspartat-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.

CAS 1332331-08-4 GSK2194069

GSK2194069
(CAS: 1332331-08-4)

GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC5...

CAS 80573-04-2 Balsalazide

Balsalazide
(CAS: 80573-04-2)

Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is a new 5-aminosalicylic acid (5-ASA) containing prodrug. It i...

CAS 65-19-0 Yohimbine HCl

Yohimbine HCl
(CAS: 65-19-0)

Yohimbine, an indole alkaloid derived from the bark of the Pausinystalia yohimbe tree in Central Africa, has been used as a mydriatic and in the treatment of im...

AT-1459
(CAS: 294658-50-7)

AT-1459 is a novel, direct thrombin inhibitor with antithrombotic efficacy (Ki = 4.9 nM).

CAS 27741-01-1 Geniposidic acid

Geniposidic acid
(CAS: 27741-01-1)

Geniposidic acid is a natural chemical compound, classified as an iridoid glucoside, found in a variety of plants including Eucommia ulmoides and Gardenia jasmi...

CAS 38976-17-9 α-Tocopherol phosphate

α-Tocopherol phosphate
(CAS: 38976-17-9)

alpha-Tocopherol is the compound demonstrating the highest vitamin E activity, which is available both in its natural form as RRR-alpha-tocopherol isolated from...

PD 130908
(CAS: 131505-02-7)

PD 130908 is an effective hypoxic cytotoxin as an analogue of RSU 1069, but less potent than the hypoxic cell radiosensitizer RSU 1069. Toxicity toward hypoxic ...

Reference Reading


1.N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis.
Fernandes BS1,2, Dean OM, Dodd S, Malhi GS, Berk M. J Clin Psychiatry. 2016 Apr;77(4):e457-66. doi: 10.4088/JCP.15r09984.
OBJECTIVE: To assess the utility of N-acetylcysteine administration for depressive symptoms in subjects with psychiatric conditions using a systematic review and meta-analysis.
2.High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K1, McEvoy CE2, Naqvi S3, Wendt C4, Reilkoff RA5, Kunisaki KM4, Wetherbee EE4, Nelson D6, Tirouvanziam R7, Niewoehner DE4. Int J Chron Obstruct Pulmon Dis. 2016 Apr 21;11:799-807. doi: 10.2147/COPD.S102375. eCollection 2016.
BACKGROUND: Clinical outcomes are worse in patients with COPD and chronic bronchitis. N-acetylcysteine (NAC) is commonly prescribed for such patients but with uncertain clinical benefits. We postulated that oral NAC, at much larger doses than those ordinarily prescribed, would improve clinical outcomes in a subset of patients with COPD and chronic bronchitis.
3.The Efficacy of Umbelliferone, Arbutin, and N-Acetylcysteine to Prevent Microbial Colonization and Biofilm Development on Urinary Catheter Surface: Results from a Preliminary Study.
Cai T1, Gallelli L2, Meacci F3, Brugnolli A4, Prosperi L4, Roberta S1, Eccher C1, Mazzoli S3, Lanzafame P5, Caciagli P6, Malossini G1, Bartoletti R7. J Pathog. 2016;2016:1590952. doi: 10.1155/2016/1590952. Epub 2016 Apr 5.
We evaluated, in a preliminary study, the efficacy of umbelliferone, arbutin, and N-acetylcysteine to inhibit biofilm formation on urinary catheter. We used 20 urinary catheters: 5 catheters were incubated with Enterococcus faecalis (control group); 5 catheters were incubated with E. faecalis in presence of umbelliferone (150 mg), arbutin (60 mg), and N-acetylcysteine (150 mg) (group 1); 5 catheters were incubated with E. faecalis in presence of umbelliferone (150 mg), arbutin (60 mg), and N-acetylcysteine (400 mg) (group 2); and 5 catheters were incubated with E. faecalis in presence of umbelliferone (300 mg), arbutin (60 mg), and N-acetylcysteine (150 mg) (group 3). After 72 hours, planktonic microbial growth and microorganisms on catheter surface were assessed. In the control group, we found a planktonic load of ≥10(5) CFU/mL in the inoculation medium and retrieved 3.69 × 10(6) CFU/cm from the sessile cells adherent to the catheter surface.